Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity (2021 - 2025)

Amylyx Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $332.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $332.6 million for Q4 2025, up 71.79% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 7.06% YoY), and the annual figure for FY2025 was $332.6 million, up 71.79%.
  • Liabilities and Shareholders Equity for Q4 2025 was $332.6 million at Amylyx Pharmaceuticals, down from $362.7 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AMLX hit a ceiling of $517.5 million in Q4 2023 and a floor of $105.6 million in Q4 2021.
  • Median Liabilities and Shareholders Equity over the past 5 years was $332.2 million (2024), compared with a mean of $313.4 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 270.64% in 2022 and later tumbled 62.58% in 2024.
  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity stood at $105.6 million in 2021, then surged by 270.64% to $391.5 million in 2022, then surged by 32.19% to $517.5 million in 2023, then tumbled by 62.58% to $193.6 million in 2024, then skyrocketed by 71.79% to $332.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $332.6 million (Q4 2025), $362.7 million (Q3 2025), and $194.6 million (Q2 2025) per Business Quant data.